Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Non Operating Investment Income (2023 - 2024)

Cartesian Therapeutics (RNAC) has disclosed Non Operating Investment Income for 2 consecutive years, with -$6.9 million as the latest value for Q1 2024.

  • On a quarterly basis, Non Operating Investment Income changed N/A to -$6.9 million in Q1 2024 year-over-year; TTM through Dec 2024 was -$6.9 million, a 95.39% increase, with the full-year FY2024 number at -$6.9 million, up 95.39% from a year prior.
  • Non Operating Investment Income was -$6.9 million for Q1 2024 at Cartesian Therapeutics, up from -$149.6 million in the prior quarter.
  • In the past five years, Non Operating Investment Income ranged from a high of -$6.9 million in Q1 2024 to a low of -$149.6 million in Q4 2023.